Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis

Inclusion Criteria: * Subject understands the study procedures and agrees to participate in the study by giving written informed consent. * Subject is 18 years of age or older. * Subject must be receiving hemodialysis 3 times weekly for at least 3 months * Subject agrees to not participate in another study of an investigational agent during the study. * Other Inclusion Criteria may apply Exclusion Criteria: * Currently receiving treatment in another investigational device or drug study, or ended treatment on another investigational device or drug study(s) within 8 weeks prior to screening. * Other investigational procedures while participating in this study are excluded. * Anticipated or scheduled parathyroidectomy during the study period. * Subject has received a parathyroidectomy within 3 months prior to dosing. * Anticipated or scheduled kidney transplant during the study period. * Subject has known sensitivity to any of the products or components to be administered during dosing. * Subject has participated in a prior clinical trial of AMG 416 (also referred to as KAI-4169). * Subject has received cinacalcet within the 4 weeks prior to screening labs (treatment with cinacalcet is prohibited during the study). * Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator. * Other Exclusion Criteria may apply